Form 4: CRISPR Therapeutics CMO Receives RSU Grant
Statement of Changes in Beneficial Ownership
Chief Medical Officer Naimish Patel was granted 22,000 restricted stock units by CRISPR Therapeutics.
Summary
- Naimish Patel, Chief Medical Officer of CRISPR Therapeutics, received an equity grant of 22,000 restricted stock units (RSUs).
- The grant was issued on May 29, 2026.
- Each RSU represents a contingent right to receive one common share of CRISPR Therapeutics (CRSP).
- The award is subject to a vesting schedule where 100% of the shares vest on November 29, 2028.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation with no immediate impact on company operations or financial health.
Positives
- Alignment of executive interests with long-term shareholder value through equity-based compensation.
- Retention of key leadership talent in the Chief Medical Officer role.
Negatives
- Potential for future shareholder dilution upon the vesting and issuance of the underlying common shares.
Risks
- Market volatility affecting the future value of the equity grant.
- Retention risk if the executive departs prior to the November 2028 vesting date.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on executive compensation disclosure.
Industry Context
StockSavvy.ai notes that equity grants to C-suite executives in the biotechnology sector are standard practice for long-term incentive alignment, particularly in R&D-heavy firms where clinical trial milestones are multi-year endeavors.
Comparison to Industry Standards
- The use of RSUs with a multi-year cliff vesting period is consistent with standard executive compensation packages at peer biotech companies like Editas Medicine and Intellia Therapeutics.
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual vesting and conversion of these units into common shares.
Next Steps
- Vesting of the 22,000 RSUs on November 29, 2028.
Key Dates
| Date | Description |
|---|---|
| 05/29/2026 | Grant date of the restricted stock units. |
| 06/02/2026 | Filing date of the Form 4. |
| 11/29/2028 | Vesting date for the 22,000 restricted stock units. |
Keywords
CRISPR Therapeutics, CRSP, Insider Trading, Form 4, Equity Compensation, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.